Business Wire

Gilead Sciences Announces First Quarter 2017 Financial Results

Del

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2017. The financial results that follow represent a year-over-year comparison of the first quarter 2017 to the first quarter 2016. Total revenues were $6.5 billion in 2017 compared to $7.8 billion in 2016. Net income was $2.7 billion or $2.05 per diluted share in 2017 compared to $3.6 billion or $2.53 per diluted share in 2016. Non-GAAP net income, which excludes amounts related to acquisition-related, up-front collaboration, stock-based compensation and other expenses, was $2.9 billion or $2.23 per diluted share in 2017 compared to $4.3 billion or $3.03 per diluted share in 2016.

  Three Months Ended
March 31,
(In millions, except per share amounts) 2017   2016
Product sales $ 6,377 $ 7,681
Royalty, contract and other revenues 128   113

Total revenues

$ 6,505   $ 7,794
 
Net income attributable to Gilead $ 2,702 $ 3,566
Non-GAAP net income* $ 2,949 $ 4,274
 
Diluted earnings per share $ 2.05 $ 2.53

Non-GAAP diluted earnings per share*

$ 2.23 $ 3.03
 

* Non-GAAP net income and non-GAAP diluted earnings per share exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.

Product Sales

Total product sales for the first quarter of 2017 were $6.4 billion compared to $7.7 billion for the same period in 2016. Product sales for the first quarter of 2017 were $4.5 billion in the United States, $1.3 billion in Europe and $661 million in other locations. Product sales for the first quarter of 2016 were $4.4 billion in the United States, $1.6 billion in Europe and $1.7 billion in other locations.

Antiviral Product Sales

Antiviral product sales, which include sales of our HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the first quarter of 2017 compared to $7.2 billion for the same period in 2016.

  • HIV and HBV product sales were $3.3 billion compared to $2.9 billion for the same period in 2016. The increase was primarily due to the continued uptake of our tenofovir alafenamide (TAF) based products, Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg).
  • HCV product sales, which consist of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi® (sofosbuvir 400 mg) and Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), were $2.6 billion compared to $4.3 billion for the same period in 2016. The decline was due to lower sales of Harvoni and Sovaldi across all major markets, partially offset by sales of Epclusa, which was launched in the United States and Europe in June and July 2016, respectively.

Other Product Sales

Other product sales, which include Letairis® (ambrisentan), Ranexa® (ranolazine) and AmBisome® (amphotericin B liposome for injection), were $536 million for the first quarter of 2017 compared to $498 million for the same period in 2016.

Operating Expenses

  Three Months Ended
March 31,
(In millions) 2017   2016
Research and development expenses (R&D) $ 931 $ 1,265
Non-GAAP R&D expenses* $ 889 $ 769
 
Selling, general and administrative expenses (SG&A) $ 850 $ 685
Non-GAAP SG&A expenses* $ 807 $ 638
 

* Non-GAAP R&D and SG&A expenses exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.

During the first quarter of 2017, compared to the same period in 2016:

  • R&D expenses decreased primarily due to the 2016 impact of up-front collaboration expenses related to Gilead’s license and collaboration agreement with Galapagos NV and impairment charges related to in-process R&D. These decreases were partially offset by expenses associated with Gilead’s purchase of a U.S. Food and Drug Administration (FDA) priority review voucher.
  • Non-GAAP R&D expenses* increased primarily due to expenses associated with Gilead’s purchase of an FDA priority review voucher.
  • SG&A expenses and non-GAAP SG&A expenses* increased primarily due to higher branded prescription drug fee expense.

Cash, Cash Equivalents and Marketable Securities

As of March 31, 2017, Gilead had $34.0 billion of cash, cash equivalents and marketable securities compared to $32.4 billion as of December 31, 2016. Cash flow from operating activities was $2.9 billion for the quarter. During the first quarter of 2017, Gilead utilized $565 million on stock repurchases and paid cash dividends of $687 million.

Full Year 2017 Guidance Reiterated

Gilead reiterates its full year 2017 guidance, initially provided on February 7, 2017:

(In millions, except percentages and per share amounts)   Initially Provided

February 7, 2017

Net Product Sales $22,500 - $24,500
Non-HCV Product Sales $15,000 - $15,500
HCV Product Sales $7,500 - $9,000
Non-GAAP*
Product Gross Margin 86% - 88%
R&D Expenses $3,100 - $3,400
SG&A Expenses $3,100 - $3,400
Effective Tax Rate 25.0% - 28.0%
Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses $0.84 - $0.91
 

* Non-GAAP Product Gross Margin, R&D and SG&A expenses and effective tax rate exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP full year 2017 guidance is provided in the tables on page 9.

Corporate Highlights

  • Announced that Alessandro Riva, MD, joined the company as Senior Vice President and therapeutic area head for hematology and oncology.
  • Announced the recipients of Gilead’s HIV cure grants program, a fund totaling more than $22 million, which will support 12 new HIV cure research projects. These projects will be conducted by leading academic institutions, non-profit organizations and community groups from around the world, focusing on three key areas: translational research, efficacy studies in animal models and community perspectives of HIV cure.

Product and Pipeline Updates announced by Gilead during the First Quarter of 2017 include:

Antiviral and Liver Diseases Programs

  • Presented data at the 2017 Conference on Retroviruses and Opportunistic Infections which included the announcement of:
  • Positive results from a Phase 2 study evaluating the efficacy, safety and tolerability of a combination of bictegravir (75 mg) (BIC) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) versus dolutegravir (50 mg) (DTG) and FTC/TAF in treatment-naïve, HIV-1 infected adults. Results found that the BIC+FTC/TAF and DTG+FTC/TAF regimens both demonstrated high virologic response rates at week 24 and week 48.
  • Positive findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment. The study identified novel HIV-1 CAIs with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro.
  • Positive 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya for the treatment of HIV-1 infection in treatment-naïve adults. Through week 144, Genvoya demonstrated significantly higher rates of virologic suppression compared to Stribild® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg), based on the percentage of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also demonstrated favorable renal and bone laboratory parameters compared to those treated with Stribild.
  • Announced that the marketing authorization application for the investigational, once-daily, single-tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of HCV-infected patients has been fully validated and is under assessment by the European Medicines Agency. Gilead also previously submitted a new drug application to FDA for SOF/VEL/VOX. Under the Prescription Drug User Fee Act, FDA has set a target action date of August 8, 2017.
  • Announced that the European Commission granted marketing authorization for Vemlidy® (tenofovir alafenamide 25mg), a once-daily tablet for the treatment of chronic hepatitis B virus infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg).

Non-GAAP Financial Information

The information presented in this document has been prepared by Gilead in accordance with U.S. generally accepted accounting principles (GAAP), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7, 8 and 9.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead’s management will host a conference call and a simultaneous webcast to discuss results from its first quarter 2017 and a general business update. To access the webcast live via the internet, please connect to the company’s website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 91219047 to access the call.

A replay of the webcast will be archived on the company’s website for one year, and a phone replay will be available approximately two hours following the call through May 4, 2017. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 91219047.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Forward-looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to achieve its anticipated full year 2017 financial results; Gilead’s ability to sustain growth in revenues for its antiviral and other programs; the risk that estimates of patients with HCV or anticipated patient demand may not be accurate; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vemlidy, Epclusa, Descovy, Odefsey and Genvoya; the potential for increased pricing pressure globally and contracting pressure as well as decreased volume and market share from additional competitive HCV launches; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs) and Veterans Administration (VA); continued fluctuations in ADAP and VA purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead’s earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada outside the United States; potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead’s earnings; Gilead’s ability to submit new drug applications and receive regulatory approval for new product candidates in the timelines currently anticipated or at all; Gilead’s ability to successfully develop its oncology, inflammation, cardiovascular and respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates, including BIC+FTC/TAF and certain HIV CAIs; Gilead’s ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead’s future revenues and pre-tax earnings; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission (SEC). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its press releases, Annual Report on Form 10-K for the year ended December 31, 2016 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, CAYSTON®, COMPLERA®, DESCOVY®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPSERA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TRUVADA®, TYBOST®, VEMLIDY®, VIREAD®, VITEKTA®, VOLIBRIS®, and ZYDELIG®.

ATRIPLA® is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. LEXISCAN® is a registered trademark of Astellas U.S. LLC. MACUGEN® is a registered trademark of Eyetech, Inc. SUSTIVA® is a registered trademark of Bristol-Myers Squibb Pharma Company. TAMIFLU® is a registered trademark of Hoffmann-La Roche Inc.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

 

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in millions, except per share amounts)

 
Three Months Ended
March 31,
2017   2016
Revenues:
Product sales $ 6,377 $ 7,681
Royalty, contract and other revenues 128   113  
Total revenues 6,505   7,794  
Costs and expenses:
Cost of goods sold 957 1,193
Research and development expenses 931 1,265
Selling, general and administrative expenses 850   685  
Total costs and expenses 2,738   3,143  
Income from operations 3,767 4,651
Interest expense (261 ) (230 )
Other income (expense), net 111   81  
Income before provision for income taxes 3,617 4,502
Provision for income taxes 918   935  
Net income 2,699 3,567
Net income (loss) attributable to noncontrolling interest (3 ) 1  
Net income attributable to Gilead $ 2,702   $ 3,566  
 
Net income per share attributable to Gilead common stockholders - basic $ 2.07 $ 2.58
Shares used in per share calculation - basic 1,308 1,383
Net income per share attributable to Gilead common stockholders - diluted $ 2.05 $ 2.53
Shares used in per share calculation - diluted 1,320 1,412
Cash dividends declared per share $ 0.52 $ 0.43
 
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in millions, except percentages and per share amounts)

 
Three Months Ended
March 31,
2017   2016
Cost of goods sold reconciliation:
GAAP cost of goods sold $ 957 $ 1,193
Acquisition related-amortization of purchased intangibles (210 ) (210 )
Stock-based compensation expenses (4 ) (3 )
Other(1)   3  
Non-GAAP cost of goods sold $ 743   $ 983  
 
Product gross margin reconciliation:
GAAP product gross margin 85.0 % 84.5

 %

Acquisition related-amortization of purchased intangibles 3.3 % 2.7

 %

Non-GAAP product gross margin(2) 88.3 % 87.2

 %

 
Research and development expenses reconciliation:
GAAP research and development expenses $ 931 $ 1,265
Up-front collaboration expenses (368 )
Acquisition related-IPR&D impairment (114 )
Stock-based compensation expenses (42 ) (41 )
Other(1)   27  
Non-GAAP research and development expenses $ 889   $ 769  
 
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses $ 850 $ 685
Stock-based compensation expenses (43 ) (44 )
Other(1)   (3 )
Non-GAAP selling, general and administrative expenses $ 807   $ 638  
 
Operating margin reconciliation:
GAAP operating margin 57.9 % 59.7

 %

Up-front collaboration expenses % 4.7

 %

Acquisition related-amortization of purchased intangibles 3.2 % 2.7

 %

Acquisition related-IPR&D impairment % 1.5

 %

Stock-based compensation expenses 1.4 % 1.1

 %

Other(1) % (0.3 )%
Non-GAAP operating margin(2) 62.5 % 69.3

 %

 
Notes:
(1) Amounts related to contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts
(2) Amounts may not sum due to rounding
 
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

(in millions, except percentages and per share amounts)

 
Three Months Ended
March 31,
2017   2016
Effective tax rate reconciliation:
GAAP effective tax rate 25.4

 %

20.8

 %

Up-front collaboration expenses

 %

(1.5 )%
Acquisition related-amortization of purchased intangibles (1.2 )% (0.7 )%
Stock-based compensation expenses(1) 0.6

 %

 %

Other(2)

 %

0.1

 %

Non-GAAP effective tax rate(3) 24.8

 %

18.7

 %

 
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead $ 2,702 $ 3,566
Up-front collaboration expenses 368
Acquisition related-amortization of purchased intangibles 202 204
Acquisition related-IPR&D impairment 99
Stock-based compensation expenses(1) 45 64
Other(2)   (27 )
Non-GAAP net income attributable to Gilead $ 2,949   $ 4,274  
 
Diluted earnings per share reconciliation:
GAAP diluted earnings per share $ 2.05 $ 2.53
Up-front collaboration expenses 0.26
Acquisition related-amortization of purchased intangibles 0.15 0.14
Acquisition related-IPR&D impairment 0.07
Stock-based compensation expenses(1) 0.03 0.05
Other(2)   (0.02 )
Non-GAAP diluted earnings per share(3) $ 2.23   $ 3.03  
 
Non-GAAP adjustment summary:
Cost of goods sold adjustments $ 214 $ 210
Research and development expenses adjustments 42 496
Selling, general and administrative expenses adjustments 43   47  
Total non-GAAP adjustments before tax 299 753
Income tax effect(1) (52 ) (45 )
Total non-GAAP adjustments after tax $ 247   $ 708  
 
Notes:
(1) Income tax effect related to stock-based compensation expenses for the three months ended March 31, 2017 include the incremental tax benefit of $20 million recognized from the adoption of Accounting Standards Update 2016-09 “Improvements to Employee Share-Based Payment Accounting”
(2) Amounts related to contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts
(3) Amounts may not sum due to rounding
 
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2017 FULL YEAR GUIDANCE

(unaudited)

(in millions, except percentages and per share amounts)

 
Initially Provided

February 7, 2017

Reiterated

May 2, 2017

Projected product gross margin GAAP to non-GAAP reconciliation:
GAAP projected product gross margin 82% - 84%
Acquisition-related expenses 4% - 4%
Non-GAAP projected product gross margin(1) 86% - 88%
 
Projected research and development expenses GAAP to non-GAAP reconciliation:
GAAP projected research and development expenses $3,295 - $3,640
Acquisition-related expenses / up-front collaboration expenses (15) - (45)
Stock-based compensation expenses (180) - (195)
Non-GAAP projected research and development expenses $3,100 - $3,400
 
Projected selling, general and administrative expenses GAAP to non-GAAP reconciliation:
GAAP projected selling, general and administrative expenses $3,305 - $3,615
Stock-based compensation expenses (205) - (215)
Non-GAAP projected selling, general and administrative expenses $3,100 - $3,400
 
Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses:
Acquisition-related expenses / up-front collaboration expenses $0.62 - $0.67
Stock-based compensation expenses 0.22 - 0.24
Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses $0.84 - $0.91
 
Note:
(1) Stock-based compensation expenses have a less than one percent impact on non-GAAP projected product gross margin
 
 

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)

   
March 31, December 31,
2017 2016 (1)
 
Cash, cash equivalents and marketable securities $ 34,017 $ 32,380
Accounts receivable, net 4,034 4,514
Inventories 1,474 1,587
Property, plant and equipment, net 2,922 2,865
Intangible assets, net 8,761 8,971
Goodwill 1,172 1,172
Other assets 5,321   5,488
Total assets $ 57,701   $ 56,977
 
Current liabilities $ 8,282 $ 9,218
Long-term liabilities 28,502 28,396
Stockholders’ equity(2) 20,917   19,363
Total liabilities and stockholders’ equity $ 57,701   $ 56,977
 
Notes:
(1) Derived from the audited consolidated financial statements as of December 31, 2016. Certain amounts have been reclassified to conform to current year presentation
(2) As of March 31, 2017, there were 1,307 million shares of common stock issued and outstanding
 
 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

(in millions)

 
Three Months Ended
March 31,
2017   2016
Antiviral products:
Harvoni – U.S. $ 926 $ 1,407
Harvoni – Europe 243 555
Harvoni – Other International 202   1,055
1,371   3,017
 
Epclusa – U.S. 735
Epclusa – Europe 138
Epclusa – Other International 19  
892  
 
Genvoya – U.S. 669 141
Genvoya – Europe 87 16
Genvoya – Other International 13   1
769   158
 
Truvada – U.S. 464 576
Truvada – Europe 189 251
Truvada – Other International 61   71
714   898
 
Atripla – U.S. 316 489
Atripla – Europe 94 143
Atripla – Other International 42   43
452   675
 
Sovaldi – U.S. 27 645
Sovaldi – Europe 106 280
Sovaldi – Other International 180   352
313   1,277
 
Stribild – U.S. 226 376
Stribild – Europe 67 81
Stribild – Other International 16   20
309   477
 
Viread – U.S. 117 123
Viread – Europe 71 76
Viread – Other International 72   73
260   272
 
Complera / Eviplera – U.S. 112 222
Complera / Eviplera – Europe 125 146
Complera / Eviplera – Other International 16   13
253   381
 
Descovy – U.S. 209
Descovy – Europe 37
Descovy – Other International 5  
251  
 
Odefsey – U.S. 203 11
Odefsey – Europe 23
Odefsey – Other International 1  
227   11
 
 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

(in millions)

 
Three Months Ended
March 31,
2017   2016
 
Other Antiviral – U.S. $ 25 $ 10
Other Antiviral – Europe 4 6
Other Antiviral – Other International 1   1
30   17
 
Total antiviral products – U.S. 4,029 4,000
Total antiviral products – Europe 1,184 1,554
Total antiviral products – Other International 628   1,629
5,841   7,183
 
Other products:
Letairis 211 175
Ranexa 153 144
AmBisome 92 86
Zydelig 35 49
Other 45   44
536   498
 
Total product sales $ 6,377   $ 7,681

Contact information

Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Sung Lee, 650-524-7792
Media
Amy Flood, 650-522-5643

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cushman & Wakefield To Acquire Its Irish Affiliate From Sherry FitzGerald Group16.7.2018 13:49Pressemelding

Global real estate services firm Cushman & Wakefield today announces it has entered into a definitive agreement to acquire the commercial property arm of Sherry FitzGerald Group in the Republic of Ireland. The deal is expected to complete in early September 2018. Cushman & Wakefield already has a 20% stake in the Irish commercial property business which operated as its exclusive affiliate in the Republic – rebranding two years ago as Cushman & Wakefield Ireland. The firm, which has more than 100 commercial property professionals and offices in Dublin, Limerick and Galway, will now be fully integrated into Cushman & Wakefield, one of the world’s largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. Managing Director Aidan Gavin becomes Cushman & Wakefield’s Head of Ireland and will also sit on the firm’s UK & Ireland Executive Committee. Cushman & Wakefield will maintain its close affiliate relationship with the wider Sherry FitzGerald G

Fischer & Schickendantz and Solution Alliance SRL Adopt Andersen Brand in Uruguay16.7.2018 13:30Pressemelding

Fischer & Schickendantz, led by Juan Federico Fischer, and Solution Alliance SRL, led by Juan Ignacio Troccoli, have rebranded this week as Andersen Tax & Legal, a member firm of Andersen Global. The firm, based in Montevideo, entered a Collaboration Agreement with Andersen Global in September 2017, and is now a fully integrated member of the global verein. Juan Federico Fischer remarked, “Andersen is a symbol of quality and is recognized worldwide by both clients and professionals, and is ahead of the game in terms of creating a global firm with integrated tax and legal services. We are truly excited to officially be part of the team.” “Throughout their time with us as a collaborating firm and now a member firm, the team in Uruguay has demonstrated a deep commitment to providing seamless, best-in-class service. Additionally, Juan Federico is a member of Andersen Global’s Latin American regional board, and is the true embodiment of the values that our organization represents. I look fo

Norsk Titanium Produces Space Demonstration Hardware16.7.2018 11:00Pressemelding

Norsk Titanium (Norsk), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, has produced an Expansion Nozzle demonstrator in support of the European Space Agency’s Technology Research Programme (TRP). The TRP is an European Space Agency (ESA) technology development effort supporting all of ESA’s fields of activity across the entire spectrum of technical disciplines, providing the technological nucleus for most future developments. Norsk was awarded a TRP contract with the ESA in 2014 to explore the application of Norsk’s Rapid Plasma Deposition™ (RPD™) process to space applications. Through the TRP contract, Norsk has refined its material characterization and quality assurance processes, while providing ESA valuable insight into the application of additive processes to their unique needs. The culmination of this effort was the production of an Expansion Nozzle demonstrator. The Expansion Nozzle utilizes the latest RPD™ desi

CALVIN KLEIN Fragrances Announces Lupita Nyong'o and Saoirse Ronan as Faces of CALVIN KLEIN WOMEN16.7.2018 11:00Pressemelding

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE:COTY], today revealed the worldwide print advertising campaign for the new fragrance CALVIN KLEIN WOMEN , the first CALVIN KLEIN fragrance to be developed under the vision of Chief Creative Officer, Raf Simons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005092/en/ CALVIN KLEIN WOMEN The campaign features Lupita Nyong'o and Saoirse Ronan. Award-winning actors and voices of their generation, both women are universally recognized for their unique talent, creativity, intelligence and strength of character. Directed by artist Anne Collier with creative direction from Lloyd & Co., the campaign champions iconic women and celebrates heroines of contemporary culture. Lupita and Saoirse are featured in the print campaign, in a pair of striking and direct portraits, positioned next to chosen figure

Bank of America Reports Second-Quarter 2018 Financial Results16.7.2018 10:45Pressemelding

Bank of America reported its second-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005280/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference ca

Bank of Singapore is the First Singapore Private Bank to Receive Regulatory Approval to Open a Wealth Management Subsidiary in Luxembourg16.7.2018 09:36Pressemelding

Bank of Singapore today announced that it has been granted an investment company licence to operate a wealth management subsidiary in Luxembourg – a first for a Singapore private bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180716005252/en/ (Photo: BOSWM) Bank of Singapore, through this new subsidiary, BOS Wealth Management Europe Société Anonyme (S.A.), will be able to offer a comprehensive range of customised private banking solutions and investment advisory services to its ultra-high and high net worth clients in the European Economic Area (“EEA”) and the United Kingdom (“UK”). The EEA comprises the European Union (EU) countries and Iceland, Liechtenstein and Norway. Currently, Bank of Singapore serves its European clients from its Singapore headquarters and through its parent company OCBC Bank’s London office. There has been robust growth in assets under management from EEA clients as they hold Singapore in high